Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy
Cancer immunotherapy has a long developmental history, beginning with William Coley’s first bacterial mixture (‘Coley’s toxin’) in 1891, which led to the development of nonspecific immunotherapy. After the research team of Thierry Boon succeeded in isolating the first melanoma antigen gene (MAGE-1)...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/25785826.2020.1785654 |